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Background: Both apoptosis and caspase-3 activity in adipose tissue-derived stem cells play an important role in
the therapeutic process of diabetes patients. The purpose of this study was to investigate the effect of advanced
glycation end products-human serum albumin (AGE-HSA) on apoptosis in human adipose tissue-derived stem cells
(ADSCs) and to characterize the signal transduction pathways activated by AGEs that are involved in apoptosis
regulation.
Results: AGE-HSA promoted apoptosis and caspase-3 activity in ADSCs. However, the effects of AGE-HSA were
significantly attenuated by an inhibitor of p38 MAPK, but not by inhibitors of JNK MAPK or ERK MAPK. AGE-HSA
also upregulated the expression of RAGE. Silencing of the RAGE gene inhibited AGE-HSA-induced apoptosis, and
activation and expression of phosphorylated p38 MAPK.
Conclusions: These results suggest that AGE-HSA promote the apoptosis of ADSCs in vitro via a RAGE-dependent
p38 MAPK pathway.
Keywords: Human adipose tissue-derived stem cells, Advanced glycation end products, Mitogen-activated
protein kinase, Apoptosis, Receptor for advanced glycation end productsBackground
Advanced glycation end products (AGEs), which are
produced by the posttranslational modification of pro-
teins via non-enzymatic glycations, accumulate with age,
and are abundantly increased in diabetic patients [1-3].
The formation and accumulation of AGEs are character-
istic of tissues from patients with diabetes mellitus and
have been strongly implicated in the pathogenesis of dia-
betic complications [4,5]. AGEs are slowly and irrevers-
ibly formed on proteins that are exposed to carbonyl
and substrate stress, especially under conditions of
hyperglycemia, hyperlipidemia and/or oxidative stress
[6]. AGEs play an important role in the pathophysio-
logical processes affecting patients with diabetes, Alzhei-
mer's disease, and aging [2,7,8]. AGEs are known to* Correspondence: wangqs18@vip.126.com
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unless otherwise stated.cause adverse side effects on the growth of several cells,
such as vascular endothelial cell and renal tubular epi-
thelial cell [9-17]. A number of studies have suggested
that AGEs mediate cell apoptosis and may play an im-
portant role in the pathogenesis of biophysical disorders
[4,6]. The elevated AGEs in diabetic patients could in-
duce a number of pathological changes, such as promot-
ing endothelial progenitor cell (EPC) and endothelial cell
apoptosis [9,18].
The receptor for advanced glycation end products
(RAGE) is a signal transduction receptor, which senses a
variety of signaling molecules including advanced glyca-
tion end products (AGEs). RAGE is a 35 kDa multili-
gand transmembrane receptor which belongs to the
immunoglobulin gene superfamily [19]. RAGE is widely
localized in many cell types such as smooth muscle cells,
hepatocytes, neurons, endothelial cells, and monocytes.
Its expression can be abnormally up or downregulated
in human diseases [20-22].RAGE is highly expressed in
the bones of diabetic animal models compared to con-
trol animals [23]. Recently, adipose tissue-derived stemThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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apy because of their simple isolation techniques, easy ex-
pandability, low immunogenicity, and pluripotency
[24,25]. ADSC therapy could potentially have a large im-
pact on the treatment of a wide variety of diseases, in-
cluding diabetes and diabetic complications. However,
increased apoptosis in stem cells has been demonstrated
in a diabetic rat model [26]. The deleterious effects of
AGEs that involve RAGE expression were reported in
stem cells [27].Nevertheless, there are few reports about
the role of RAGE in ADSC therapy in complaint such as
diabetes.
AGEs have been reported to activate serine-threonine
protein kinases in the mitogen-activated protein kinase
(MAPK) pathways. C jun N terminal kinase (JNK) and
p38 MAPK are the two major subfamilies of MAPKs that
participate in apoptosis. AGEs are known to induce osteo-
blast apoptosis via both JNK and p38 MAPK [15,17,27].
Despite ADSC administration was reported to improve
healing in diabetic skin repair [28,29], it remains unclear if
AGEs could affect the apoptosis of ADSCs during the
therapeutic process in diabetes patients. The purpose ofFigure 1 Characterization of ADSCs and the effect of AGE-HSA on CD10
ADSCs on the first day. (B) Adherent ADSCs 3 days after plating, showing a sp
morphologies and had reached near-confluence. Scale bar is equivalent to 50
isotype controls against the indicated antigens and analyzed by flow cytomet
ADSCs expressed CD105 and CD90, but not CD34, CD14, CD45 or HLA-DR. AGthe present study was to determine the effect of ad-
vanced glycation end products-human serum albumin
(AGE-HSA) on ADSC apoptosis and to investigate the
underlying molecular mechanism. The results of this
study could lay a cellular basis for more effectively using
ADSCs to treat diabetes and diabetic complications.Results
Characterization of ADSCs
ADSCs were isolated from human adipose tissue. As
shown in Figure 1, adherent cells were seen after 1 d in
culture (Figure 1A). After 3–4 d in culture, the cells had a
short spindle shape (Figure 1B). Most of the cells exhib-
ited fibroblast-like morphologies and were nearly conflu-
ent after 10 d in culture (Figure 1C). To characterize the
cell surface marker profile of stem cells from human adi-
pose tissue, cells from the third passage were analyzed by
FACS. FACS showed that ADSCs expressed CD105 and
CD90, but not CD34, CD14, CD45 or HLA-DR, consist-
ent with previous reports [10] (Figure 1D). The cells were
incubated with HSA (300 μg/ml) or AGE-HSA (300 μg/5 and CD90 expression in ADSCs. (A) Representative image of isolated
indle shape. (C) After 10 days, most of the ADSCs exhibited fibroblast-like
μm. (D) Passage 3 ADSCs were labeled with antibodies or matching
ry to obtain representative immunophenotypes. FACS showed that
E-HSA altered CD105 and CD90 expression in ADSCs.
Figure 2 The effect of AGE-HSA on apoptosis and caspase-3
activity in ADSCs. The cells were incubated with HSA (300 μg/ml)
or AGE-HSA (50–500 μg/ml) for 24 h. The level of apoptosis (A) and
caspase-3 activity assay (B) were measured by ELISA. Each value is
expressed as the mean ± SD of three independent experiments.
*p < 0.05 vs. control (HSA 300 μg/ml).
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vious decrease in the percentage of cells expressing the
stem cell-specific markers (CD105 and CD90) (Figure 1D
and Table 1).
Effects of AGE-HSA on apoptosis and caspase-3 activity of
ADSCs
The cells were incubated with HSA (300 μg/ml) or
AGE-HSA at concentrations ranging from 50–500 μg/
ml for 24 h. As shown in Figure 2, the cells treated with
AGE-HSA showed an increase in apoptotic cell death
compared to control cells (Figure 2A). Because caspase-
3 is the principal effector caspase through which the
mitochondrial and cytosolic pathways induce apoptosis,
the levels of caspase-3 activity in each group were mea-
sured (Figure 2B). AGE-HSA significantly increased the
caspase-3 activity in treated cells compared to control
cells.
Effects of AGE-HSA on expression of RAGE of ADSCs
The effects of AGEs are mediated by interaction with or
uptake by RAGE. To determine whether AGE-HSA might
affect the expression of RAGE in ADSCs, the cells were
incubated with HSA (300 μg/ml) or AGE-HSA (50–
500 μg/ml) for 24 h, and then the expression of RAGE
was determined by RT-PCR and western blot. As shown
in Figure 3, cells treated with AGE-HSA showed an in-
crease in expression of RAGE mRNA levels (Figure 3A
and C) and protein levels (Figure 3B and C).
Role of MAPK pathway in AGE-HSA-promoted apoptosis
of ADSCs
To determine whether the activation of MAPK was ne-
cessary for AGE-HSA-induced apoptosis in ADSCs,
the cells were pre-treated for 60 min with pharmaco-
logical inhibitors of MAPK signaling pathways (U0126,
SB203580, and SP600125). The cells were then treated
with 300 μg/ml AGE-HSA for 24 h. Pre-treatment with
the p38 inhibitor (SB203580) significantly reduced the
AGE-HSA-mediated increase in apoptosis (Figure 4A)
and caspase-3 activity (Figure 4B). Compared with the
control group, SB203580 alone did not affect apoptosis
(Figure 4A) and caspase-3 activity (Figure 4B). In con-
trast, U0126 (ERK) and SP600125 (JNK) had no effect
on the level of apoptosis and caspase-3 activityTable 1 Effects of AGE-HSA on cell surface antigen
expression of ADSCs
Marker HSA (300 μg/ml) AGE-HSA (300 μg/ml)
CD105 97.5 ± 2.01 39 ± 4.27*
CD90 96.9 ± 1.95 28.5 ± 6.14*
*p < 0.05 vs. control (HSA 300 μg/ml).induced by AGE-HSA. To further establish whether
p38 MAPK phosphorylation was required for AGE-
HSA induced apoptosis, cells were serum-starved and
treated with AGE-HSA then analyzed for ERK1⁄2, p38,
and JNK MAPK phosphorylation levels. p38 phosphoryl-
ation was rapidly induced in response to AGE-HSA. The
peak response was obtained within 30 min and then phos-
phorylation declined to almost the basal level within
60 min. (Figure 4C-D). In contrast, AGE-HSA had no ef-
fect on activation of ERK1/2 and JNK MAPK (Figure 4E-
H). These data indicated that the activation of p38 MAPK,
but not the ERK1⁄2 and JNK pathways, was involved in
AGE-HSA-induced apoptosis in ADSCs.
Effects of RAGE siRNA on apoptosis and caspase-3 activity
of ADSCs induced by AGE-HSA
To test whether siRNA could silence RAGE expression,
we treated ADSCs with three different RAGE siRNAs.
Figure 3 The effect of AGE-HSA on expression of RAGE. (A) Representative RT-PCR images showing mRNA expression levels of RAGE.
(B) Representative Western blot images showing the protein expression levels of RAGE. (C) Densitometric analyses of RT-PCR and Western blots
as a percentage of GAPDH expression. Each value is expressed as the mean ± SD of three independent experiments. *p < 0.05 vs. control
(HSA 300 μg/ml).
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mRNA expression were 87.3% (Target 1), 72.9% (Target
2), and 90.9% (Target 3) for each of the different siR-
NAs (Figure 5B) RAGE mRNA downregulation was
paralleled by a decrease in RAGE protein abundance.
The percentages of inhibition for RAGE protein expres-
sion were 71.5% (Target 1), 81.7% (Target 2), and 89.1%
(Target 3) at 24 h (Figure 5C). Because Target 3 ap-
peared to be the most effective at inhibiting RAGE mRNA
and protein expression, this siRNA was used for subse-
quent experiments.
We next evaluated whether silencing the RAGE gene
might affect the level of apoptosis and caspase-3 activity
of ADSCs induced by AGE-HSA. The mock-, control
siRNA- or RAGE siRNA-transfected ADSCs were sup-
plemented with either HSA or AGE-HSA (300 μg/ml)
for 24 h. The level of apoptosis and caspase-3 activity
was then quantified by ELISA. No significant differences
were observed in the level of apoptosis or caspase-3 ac-
tivity between the three groups in the cells treated with
HSA. However, after incubation with AGE-HSA, the
level of apoptosis (Figure 6A) and caspase-3 activity
(Figure 6B) was partly inhibited by the RAGE-specific
siRNA compared to the control siRNA. In the groups
that were mock transfected or transfected with control
siRNA, the levels of apoptosis and caspase-3 activity
were not significantly different.Effects of RAGE siRNA on p38 MAPK activation of ADSCs
induced by AGE-HSA
To determine whether silencing the RAGE gene affected
AGE-HSA mediated signaling downstream in the MAPK
pathway, we evaluated p38 MAPK phosphorylation in
the mock-, control siRNA- RAGE siRNA-, or RAGE
siRNA + PCDNA3.1-RAGE expression construct (rescue)
transfected ADSCs. The cells were supplemented with
either HSA or AGE-HSA (300 μg/ml) for 24 h. Then,
p38 MAPK phosphorylation and RAGE was quantified
by Western blot analysis. No significant differences in
the phosphorylation of p38 were observed between the
three groups treated with HSA. However, after incuba-
tion with AGE-HSA, the phosphorylation of p38 was
partly inhibited by the RAGE-specific siRNA compared
with the non-binding control siRNA (Figure 6C-D). In
groups that were mock transfected, transfected with
control siRNA or in rescue condition, the p38 phosphor-
ylation was not significantly different. Moreover, the ex-
pression of RAGE in these cells was also quantified by
Western blot analysis (Figure 6E-F).
Discussion
ADSCs have similar features to MSCs from other tis-
sues such as a high proliferative rate and the potential
to differentiate into diverse cell lineages of both meso-
dermal and nonmesodermal origin. Moreover, ADSCs
Figure 4 Role of the MAPK pathway in AGE-HSA induced apoptosis in ADSCs. The effect of a p38 MAPK inhibitor on apoptosis and caspase-3
activity in ADSCs induced by AGE-HSA. (A, B) Pre-treatment with a p38 inhibitor (SB203580) significantly reduced AGE-HSA induced increase
in apoptosis and caspase-3 activity. (C,E, G) Representative western blot images showing protein expression of phosphorylated p38, ERK and
JNK (p-p38, p-ERK and p-JNK). (D, F, H) Densitometric analyses of Western blots showing the level of p-p38, p-ERK and p-JNK as a percentage
of total p38, ERK and JNK. Each value is expressed as the mean ± SD of three independent experiments. *p < 0.05 vs. control (HSA 300 μg/ml);
# p < 0.05 vs. AGE-HSA group.
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Figure 5 Knockdown of RAGE mRNA and protein expression levels using siRNA. Serum-starved ADSCs were transfected with different double-
stranded siRNAs at a final concentration of 50 nM each. RAGE mRNA and protein expression levels at 48 h after transfection were quantified.
(A) Representative RT-PCR experiments illustrating RAGE mRNA expression in ADSCs at 48 h after transfection with different siRNAs. (B) Data
shown are the percent inhibition of RAGE mRNA expression levels compared to mock-transfected cells. The mean ± SD of three independent
experiments are shown. (C) Representative Western blotting experiment illustrating RAGE protein expression in ADSCs 48 h after transfection
with different siRNAs. (D) Data shown are the percent inhibition of RAGE protein expression in ADSCs 48 h after transfection with different siRNAs. The
means ± SD of three independent experiments are shown. “Mock” indicates “mock-transfected cells”, meaning cells were only transfected with
transfection reagents. *p < 0.05 vs. control siRNAs.
Wang et al. Cell & Bioscience 2015, 5:3 Page 6 of 10
http://www.cellandbioscience.com/content/5/1/3are also abundant and easy to sample in adults, which
could potentially allow them to be used for autologous
transplantation [24-27]. Recent preclinical studies have
shown the beneficial effect of ADSC administration for
treating a wide variety of diseases, including in animal
models of diabetes [28-31]. However, the expansion and
differentiation of ADSCs in vitro could be affected by
many factors including: growth factors, chemical signals,
and seeding density that may all indirectly influence the
subsequent therapeutic effects. In addition, the culture
media components may influence stem cell proliferation
replicative senescence, and apoptosis [26].
AGEs have been shown to stimulate the activation of
MAPK cascades in different cell types [11-15]. Further-
more, MAPK signals are robustly activated in a variety
of disease states and have been implicated in mediating
apoptotic responses. AGEs have been reported to in-
duce apoptosis in osteoblasts and fibroblasts via the
JNK and p38 MAPK pathways [16,17]. Based on these
data, we hypothesized that AGE-HSA induced apop-
tosis in ADSCs could involve the MAPK pathways.
Thus, we investigated the role of p38, ERK1⁄2, and JNKMAPK signaling in apoptosis and caspase-3 activity in
ADSCs. Our data showed that AGE-HSA induced the
phosphorylation of p38 MAPK, and that pretreatment
with SB203580 inhibited AGE-HSA-induced apoptosis,
suggesting that p38 MAPK potentially played an important
role in regulating AGE-HSA induced apoptosis. In con-
trast, specific inhibitors of ERK and JNK, had no effect on
the level of apoptosis in ADSCs.
RAGE is the best-characterized AGE receptor and is
responsible for most of the damaging effects of AGEs
[32-34]. Here, we demonstrated that ADSCs expressed
RAGE protein and that the incubation of ADSCs with
AGE-HSA resulted in significant upregulation of RAGE
expression. Our results were consistent with Kume
et al., who showed that MSCs expressed RAGE, and that
its induction was stimulated by AGE-2 and AGE-3. Pre-
vious reports have shown that downstream apoptotic
signals from RAGE can be mediated through the p38
MAPK and JNK pathways. In osteoblast cells CML-
collagen-induced apoptosis, and therefore impaired bone
formation, was reduced by p38 MAPK (45%) or JNK
(59%) inhibitors, and the effect was additive as treatment
Figure 6 Effects of RAGE siRNA on p38 MAPK activation in ADSCs induced by AGE-HSA. (A, B) The mock-, control siRNA- and RAGE siRNA-
transfected ADSCs were cultured with 300 μg/ml AGE-HSA or HSA for 24 h and then subjected to an ELISA to measure apoptosis and caspse-3
activity. (C) The mock-, con siRNA- and RAGE siRNA-transfected ADSCs were stimulated with 300 μg/ml AGE–HSA for 30 min. Phosphorylation of
p38 MAPK was determined by Western blotting. Representative western blot images showing the protein expression of total p38 MAPK and
phosphorylated p38 MAPK (p-p38) are shown. (D) Densitometric analyses of the western blots showing the level of p-p38 as a percentage of total
p38. Each value is expressed as the mean ± SD of three independent experiments. “Mock” indicates “mock-transfected cells”, meaning cells were
only transfected with transfection reagents. “Rescue” indicates cells in rescue condition (RAGE siRNA + RAGE expression). (E) The mock-, con
siRNA- and RAGE siRNA-transfected ADSCs were stimulated with 300 μg/ml AGE–HSA for 30 min. Expression of RAGE was determined by Western
blotting. Representative western blot images showing the protein expression of RAGE and GAPDH are shown. (F) Densitometric analyses of the
western blots showing the level of RAGE as a percentage of GAPDH. Each value is expressed as the mean ± SD of three independent experiments.
*p < 0.05 vs. control siRNA.
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cell apoptosis [21]. Furthermore, AGE-mediated apop-
tosis in endothelial progenitor cells was shown to be
significantly inhibited by anti-RAGE neutralizing antibody
[35]. To confirm the involvement of RAGE in mediating
apoptosis by AGE-HSA, we used an siRNA approach to
block RAGE in ADSCs. We found that siRNAs signifi-
cantly suppressed AGE-HSA stimulated apoptosis. These
results demonstrate the critical role of RAGE in medi-
ating stem cell survival and highlight the importance ofthe RAGE ligand axis in ADSC therapy for diabetes.
Furthermore, knocking down RAGE expression re-
sulted in an obvious decrease in the level of p38 MAPK
phosphorylation stimulated by AGE-HSA. This suggests
that the activation of p38 MAPK stimulated by AGE-HSA
might be RAGE dependent.
Conclusion
The present study demonstrates AGEs increased apop-
tosis of ADSCs via a RAGE-p38 MAPK-mediated
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sults could provide insights about how to block the ad-
verse effects of AGEs on ADSCs, and could lead to
improvements in the clinical application of ADSCs.Materials and methods
Cell culture
This study was conducted in accordance with the ethical
standards laid out in the Declaration of Helsinki (1975)
and was approved by the Institutional Ethics Committee
at China Medical University. Adipose tissue samples
were obtained with informed consent from patients at
Shengjing Hospital. The ADSCs were isolated and har-
vested as previously described [24]. Briefly, adipose tis-
sues were digested with type I collagenase (Roche
Diagnostic, Mannheim, Germany) under gentle agitation
at 37°C for 30 min. The enzyme activity was neutralized
with FBS, and the suspensions were centrifuged at 300
g for 10 min to remove floating mature adipocytes. The
cells were seeded into DMEM medium supplemented
with 10% FBS. The cultures were maintained at 37°C in
a 5% CO2 incubator. After 48 h, non-adherent cells
were removed, and adherent cells were washed 3 times
with phosphate-buffered saline (PBS). The medium was
changed every 3 days, and the cells were subcultured
when the monolayer of adherent cells reached conflu-
ence. ADSCs were used in experiments between pas-
sages 3–6.Cell identification
Flow cytometry was used to detect cell surface markers
on the cultured cells. The cells were trypsinized with
0.05% trypsin-EDTA, collected in regular mesenchymal
cell media, and centrifuged for 5 min at 800 g at 4°C.
Then, the cells were resuspended in PBS containing 1%
bovine serum albumin at 106 cells/ml and incubated
with monoclonal PE-conjugated antibodies for CD45,
CD34, CD14, and HLA-DR; an FITC-conjugated anti-
bodies for CD90 and CD105 or matching isotype con-
trols (all from Becton-Dickinson, USA) for 45 min on
ice. The cells were subsequently washed with PBS, fixed
with 1% formaldehyde, and analyzed by flow cytometry.
A minimum of 10,000 cell events per sample were ac-
quired on a FACSCalibur flow cytometer.Treatment with specific inhibitors
For some experiments, specific inhibitors were added to
cells and incubated for 60 min before treatment with
AGE-HSA (St. Louis, USA). The ERK inhibitor (U0126),
JNK inhibitor (SB203580), and p38 inhibitor (SP600125)
were purchased from Santa Cruz Biotechnology (Santa
Cruz, CA, USA).Small interfering RNA transfection and contransfection
Cells were plated in 6 cm2 dishes (4 × 105 cells per dish).
The cells were grown to 70% confluence and transfected
with siRNA complexes or transfection reagents alone
(mock transfection) using Lipofectamine 2000 (Gibco
BRL) according to manufacturer’s instructions as previously
described [29]. A scramble siRNA duplex (fluorescein) was
used as a negative control. In the rescue condition, subjects
were cotransfected with siRNA and a PCDNA3.1-RAGE
expression construct.The final concentration of siRNA used
for each transfection was 50 nM.
Apoptosis assay
For the apoptosis assays, cells were plated in 96-well
plates at a density of 2.0 × 104 cells per well. They were
incubated until they were approximately 80% confluent,
and then they were changed to the assay medium. To in-
duce apoptosis, ADSCs were exposed to HSA (300 μg/
ml) or AGE-HSA at various concentrations (50-500 μg/
ml) for 24 h. To determine the role of different signaling
pathways in apoptosis, ADSCs were pretreated with
MAPK inhibitors U0126(50 μmol/l), SB203580(10 μmol/
l), SP600125 (50 μmol/l), or RAGE siRNA for 60 min
where indicated, and then apoptosis was induced with
300 μg/ml AGE for 24 h. The level of apoptosis was de-
termined using the Cell Death Detection ELISAPLUS kit
(Roche Applied Science, Indianapolis, IN), which detects
cytoplasmic histone-associated DNA fragments, accord-
ing to the manufacturer’s instructions as previously re-
ported [4]. Absorbance was measured at 405 nm with a
PowerWave 2 multiplate reader spectrophotometer.
Caspase-3 activity assay
As a marker of apoptosis, Caspase-3 activation was
assessed using the Caspase-Glo3/7 Assays (Promega,
Madison, USA). Cells were plated in 96-well plates at a
density of 2.0 × 104 cells per well and incubated for 24 h.
The cells were treated as described above in the apoptosis
assay. After the cells were treated, 60 μl of the supernatant
was aliquoted from each well to a new 96-well plate. An
equal volume of Caspase-Glo 3/7 reagents were added,
and then incubated for 1 h at room temperature before
measuring the luminescence of the samples.
RNA extraction and reverse transcription-polymerase
chain reaction (RT-PCR)
RT-PCR was performed as previously described [24].
Briefly, total RNA was extracted from each sample
using Trizol reagent (Invitrogen) according to the man-
ufacturer’s instructions, and dissolved in DEPC-treated
water. The quality of the isolated RNA was checked by
agarose gel electrophoresis, and RNA concentration
was determined by measuring optical density at 260
and 280 nm. Total RNA (2 μg) in a final volume of
Table 2 Sequences of primers and PCR conditions




RAGE S: 5′-CTGGTGTTCCCAATAAGG-3′ 372 58.5/38
AS: 5′-AGGTCAGGGTTACGGTT-3′
GAPDH S: 5′-ACCACAGTCCATGCCATCAC-3′ 452 56.0/26
AS: 5′-TCCACCACCCTGTTGCTGTA-3′
S, sense; AS, antisense; Ta, annealing temperature.
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thesis was carried out using random hexamer primers
and MMLV reverse transcriptase, under the conditions
recommended by the manufacturer (Invitrogen). Spe-
cific primers were manually designed using Gene Run-
ner software (Hastings Software, Inc.). Sequences of
primers and PCR conditions used are shown in Table 2.
Plasmid construction
ADSCs were lysed with isogen reagent (Nippon Gene,
Tokyo, Japan) for RNA extraction. Total RNAs were re-
verse transcribed with SuperScript II Reverse Transcriptase
(Takara) into cDNA. The full length human RAGE CDS
sequence was amplified by PCR and specific primers with
kpn1 restriction sites were designed according to sequence
number NM_001206954.1 on (http://www.ncbi.nlm.nih.
gov ). Full length RAGE was inserted into a pCDNA3.1
vector to construct a mammalian expression plasmid
(PCDNA3.1-RAGE). Successful insertion was confirmed
by sequencing.
Western blot analysis
Protein was isolated from harvested cells using mechan-
ical disruption and the Mammalian Cell Lysis Kit
(Sigma-Aldrich, St Louis, MO) according to the manu-
facturer’s instruction. The proteins were separated on
1 mm NuPage Novex 10% Bis-Tris gels using the
NuPage MOPS SDS Buffer Kit (Life Technologies, Carls-
bad, CA, USA) followed by electrotransfer to 0.2 mm
nitrocellulose membranes (Pall, Port Washington, WI,
USA). Nonspecific binding sites were blocked with 5%
bovine serum albumin in PBS for 1 hour at room
temperature (RT). Membranes were then incubated with
diluted primary antibody (1:1000; Cell Signaling Tech-
nology, Inc.) at 4°C overnight. Following three washes
with PBS containing 0.5% Tween-20, membranes were
incubated with diluted secondary antibody (GE Health-
care, Buckinghamshire, UK) at RT for two hours. The
signal was visualized with an enhanced chemilumines-
cent reagent (Amersham Biosciences, Piscataway, NJ).
For the protein loading control, blots were stripped and
stained for GAPDH using an anti-GAPDH antibody
(1:2000, AbCam, Cambridge, MA).Statistical analysis
Statistical analysis was performed using SPSS version
19.0 software. Data are presented as means ± standard
deviation (SD). Univariate comparisons of the means
were performed using the Student’s t test with a sig-
nificance threshold of p < 0.05. The data shown in the
figures are representative of three independent
experiments.
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